Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
Fcrn Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Therapeutic Advances and Clinical Outcomes Publisher Pubmed



Ma Nilforoshzade Mohammad ALI ; N Heidari NAZILA ; Sa Hosseini Seyed AYIN ; N Ghotbi NEGAR ; M Abdollahi Namanloo MAHDI ; A Heidari AMIRHOSSEIN
Authors

Source: Cytokine Published:2025


Abstract

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts, leading to bleeding risks. Despite existing treatments, many patients with chronic or refractory ITP remain inadequately managed. Fc-receptors, including neonatal Fc receptor (FcRn), play a crucial role in the ITP pathogenesis by activating antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis, leading to platelet destruction. In addition, recent insights highlight cytokine dysregulation, particularly involving interleukin (IL)-17, IL-6, and Interferon-gamma (IFN-γ), as contributing to disease persistence and immune dysfunction. We sought to evaluate the efficacy and safety of FcRn inhibitors for chronic or persistent ITP treatment. PubMed/Medline, Scopus, and Web of Science databases were systematically searched until January 16th, 2025. Preclinical and clinical studies with available full-text in English were included. Efgartigimod significantly improved platelet counts and reduced Immunoglobulin G (IgG) levels in refractory as well as chronic patients with minimal adverse effects. Rozanolixizumab also showed favorable outcomes in terms of platelet count elevation and IgG reduction in Phase 2 and Phase 3 clinical trials in cases who were unresponsive to ≥2 standard-of-care ITP treatments. These immunotherapeutic agents can effectively increase platelet counts and reduce IgG serum levels, addressing a critical need in patients who do not respond to corticosteroids, thrombopoietin receptor agonists (TPO-RAs), and rituximab. Further long-term studies are warranted to confirm these findings and explore their broader clinical implications. © 2025 Elsevier B.V., All rights reserved.
Related Docs
View other Related Docs
1. Multi-Omics Insights Into Autoimmune Thrombocytopenic Purpura, Comprehensive Hematology and Stem Cell Research: Volume 1-5 (2024)
2. Efficacy and Safety of Syk and Btk Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence, Mediators of Inflammation (2025)
3. The Role of Baff and Baff-R Inhibitors in the Treatment of Immune Thrombocytopenia; a Focused Review, International Immunopharmacology (2024)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (3)
Mohammad Vaezi (1)
Other Related Docs
4. When the Victim Becomes the Villain: Platelets As Drivers of Immune Dysregulation in Itp, Journal of Translational Autoimmunity (2025)
5. Significant Immunomodulatory and Hepatoprotective Impacts of Silymarin in Ms Patients: A Double-Blind Placebo-Controlled Clinical Trial, International Immunopharmacology (2021)
6. Toll-Like Receptor 7 Regulates Cardiovascular Diseases, International Immunopharmacology (2022)
7. Investigating the Refractory Platelet Transfusion: Understanding the Underlying Factors, Diagnosis, and Effective Treatment Strategies, Iranian Journal of Blood and Cancer (2025)
8. Covid-19 Associated Thrombotic Thrombocytopenic Purpura (Ttp); a Case Series and Mini-Review, International Immunopharmacology (2021)
9. Il-22 Produced by T Helper Cell 22 As a New Player in the Pathogenesis of Immune Thrombocytopenia, Endocrine# Metabolic and Immune Disorders - Drug Targets (2015)
10. Inflammation As a Cause of Venous Thromboembolism, Critical Reviews in Oncology/Hematology (2016)
11. A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. Coli, Recent Patents on Biotechnology (2024)
12. Recent Advances in Treatment Crimean–Congo Hemorrhagic Fever Virus: A Concise Overview, Microbial Pathogenesis (2022)
13. A Comprehensive Overview of Coagulation Factor V and Congenital Factor V Deficiency, Seminars in Thrombosis and Hemostasis (2019)
14. Laboratory Diagnosis of Factor Xiii Deficiency, Routine Coagulation Tests With Quantitative and Qualitative Methods, Clinical Laboratory (2016)
15. Inflammation in Venous Thromboembolism: Cause or Consequence?, International Immunopharmacology (2015)
16. Cellular Mechanisms and Clinical Applications for Phenocopies of Inborn Errors of Immunity: Infectious Susceptibility Due to Cytokine Autoantibodies, Expert Review of Clinical Immunology (2023)
17. Primary Immunodeficiency and Thrombocytopenia, International Reviews of Immunology (2022)
18. Comparing Effects of Different Routes of Heparin Administration on the Serum Biomarkers of Thrombosis, Journal of Comparative Effectiveness Research (2016)
19. Patient and Physician Perspectives in the Management of Immune Thrombocytopenia in Iran: Responses From the Itp World Impact Survey (I-Wish), Clinical and Applied Thrombosis/Hemostasis (2023)
20. Two Ischemic Stroke Events Within 48 H: A Case Report of an Unusual Presentation of Thrombotic Thrombocytopenic Purpura, BMC Neurology (2023)